이
이언형 Director
Board M
KR KR · DART (FSS)
Browse the detailed record of transactions filed by 이언형, Director. Insider active across 2 companies, notably 셀트리온제약. In total, 5,485 reports have been published. The latest transaction was filed on 4 March 2026 — Purchase. Regulator: DART (FSS). The full history is openly available.
Declarations 5,485 total
€23,378 950 shares @ €24.608 0.0000% mcap 100.0% of flow
DART:20260515002789 · 8 May 2026
Executives ● PurchaseD DB증권 17 DART €7,973 1,000 shares @ €7.9729 0.0000% mcap 41.0% of flow
DART:20260515002900 · 14 May 2026
Ideal exit: 8 Feb 2027 (T+270) €3m 9,443 shares @ €297.3701 0.0000% mcap 7.5% of flow
DART:20260515002814 · 8 May 2026
Ideal exit: 2 Feb 2027 (T+270) DART:20260515002905 · 15 May 2026 details not loaded
Executives ● Purchase휴 휴마시스 11 DART €879,604 381,422 shares @ €2.3061 0.0009% mcap 100.0% of flow
DART:20260515002044 · 13 May 2026
Ideal exit: 7 Feb 2027 (T+270) €58,186 7,900 shares @ €7.3654 0.0001% mcap 76.6% of flow
DART:20260515002070 · 11 May 2026
€2m 1,293,660 shares @ €1.3566 0.0044% mcap 100.0% of flow
DART:20260515000829 · 8 May 2026
Ideal exit: 2 Feb 2027 (T+270) Executives ● Purchase유 유니크 24 DART €34,159 13,000 shares @ €2.6276 0.0000% mcap 13.8% of flow
DART:20260515001481 · 11 May 2026
Ideal exit: 5 Feb 2027 (T+270) Executives ● Purchase케 케이티 15 DART DART:20260515001559 · 15 May 2026
Ideal exit: 9 Feb 2027 (T+270) Executives ● Purchase앱 앱토크롬 2 DART DART:20260515001598 · 15 May 2026
Ideal exit: 9 Feb 2027 (T+270) Executives ● Purchase가 가온전선 14 DART €102,215 333 shares @ €306.9534 0.0000% mcap 51.8% of flow
DART:20260515001775 · 15 May 2026
Ideal exit: 9 Feb 2027 (T+270) Executives ● Purchase한 한솔홀딩스 28 DART €2,290 902 shares @ €2.5384 0.0000% mcap 33.1% of flow
DART:20260515001778 · 13 May 2026
Ideal exit: 7 Feb 2027 (T+270) Executives ● Sale앱 앱토크롬 2 DART DART:20260515001938 · 15 May 2026
Executives ● Sale파 파버나인 3 DART €2m 1,022,146 shares
DART:20260515001628 · 15 May 2026
Executives ● Purchase대 대성미생물 31 DART €11,719 3,000 shares @ €3.9062 0.0000% mcap 100.0% of flow
DART:20260515001671 · 15 May 2026
Ideal exit: 9 Feb 2027 (T+270) Executives ● Purchase가 가온전선 32 DART €95,971 280 shares @ €342.7547 0.0000% mcap 84.5% of flow
DART:20260515001848 · 15 May 2026
Ideal exit: 9 Feb 2027 (T+270) Executives ● Purchase휴 휴마시스 3 DART €872,947 381,422 shares
DART:20260515001992 · 15 May 2026
Ideal exit: 9 Feb 2027 (T+270) 256,792 shares
DART:20260515002117 · 15 May 2026
€5,357 37,366 shares @ €13.3926 0.0000% mcap 100.0% of flow
DART:20260515002263 · 31 Oct 2025
Executives ● Purchase유 유니크 20 DART €2,521 1,000 shares @ €2.5212 0.0000% mcap 100.0% of flow
DART:20260515001580 · 13 May 2026
Ideal exit: 7 Feb 2027 (T+270) Executives ● Purchase한 한솔홀딩스 5 DART €1,914 902 shares
DART:20260515002076 · 15 May 2026
Ideal exit: 9 Feb 2027 (T+270) Executives ● Sale하 하나투어 35 DART €120,702 5,000 shares @ €24.1404 0.0000% mcap 100.0% of flow
DART:20260515002262 · 7 May 2026
DART:20260515000127 · 15 May 2026 details not loaded
Executives ● Purchase일 일정실업 3 DART €90,204 66,919 shares
DART:20260515000220 · 15 May 2026
Ideal exit: 9 Feb 2027 (T+270) €7,984 880 shares @ €9.0732 0.0000% mcap 1.5% of flow
DART:20260515000306 · 12 May 2026
Ideal exit: 6 Feb 2027 (T+270) 25 of 5485 declarations
Load more (5460 remaining) About 이언형 Eun-hyung Lee is a Board Member at Celltrion Pharmaceutical, an innovative company in the pharmaceutical sector. In his role, Eun-hyung participates in strategic decision-making and oversees the company's activities. His expertise is valuable for the future development of Celltrion Pharmaceutical.